BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28536279)

  • 1. The Damaging Effect of Passenger Mutations on Cancer Progression.
    McFarland CD; Yaglom JA; Wojtkowiak JW; Scott JG; Morse DL; Sherman MY; Mirny LA
    Cancer Res; 2017 Sep; 77(18):4763-4772. PubMed ID: 28536279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes.
    McFarland CD; Mirny LA; Korolev KS
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15138-43. PubMed ID: 25277973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of deleterious passenger mutations on cancer progression.
    McFarland CD; Korolev KS; Kryukov GV; Sunyaev SR; Mirny LA
    Proc Natl Acad Sci U S A; 2013 Feb; 110(8):2910-5. PubMed ID: 23388632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer.
    Gatenby RA; Brown J
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):162-166. PubMed ID: 28341421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.
    Buisson R; Langenbucher A; Bowen D; Kwan EE; Benes CH; Zou L; Lawrence MS
    Science; 2019 Jun; 364(6447):. PubMed ID: 31249028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M; Yao J; Yu D
    Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing mutational and adaptive landscapes and the genesis of cancer.
    Liggett LA; DeGregori J
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of constrained cancer driver genes based on mutation timing.
    Sakoparnig T; Fried P; Beerenwinkel N
    PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using passenger mutations to estimate the timing of driver mutations and identify mutator alterations.
    Youn A; Simon R
    BMC Bioinformatics; 2013 Dec; 14():363. PubMed ID: 24330428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations of the Driver/Passenger Model in Cancer Prevention.
    Kuhner MK; Kostadinov R; Reid BJ
    Cancer Prev Res (Phila); 2016 May; 9(5):335-8. PubMed ID: 26932841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.
    Bányai L; Trexler M; Kerekes K; Csuka O; Patthy L
    Elife; 2021 Jan; 10():. PubMed ID: 33427197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T24 HRAS transformed NIH/3T3 mouse cells (GhrasT-NIH/3T3) in serial tumorigenic in vitro/in vivo passages give rise to increasingly aggressive tumorigenic cell lines T1-A and T2-A and metastatic cell lines T3-HA and T4-PA.
    Ray DB; Merrill GA; Brenner FJ; Lytle LS; Lam T; McElhinney A; Anders J; Rock TT; Lyker JK; Barcus S; Leslie KH; Kramer JM; Rubenstein EM; Pryor Schanz K; Parkhurst AJ; Peck M; Good K; Granath KL; Cifra N; Detweiler JW; Stevens L; Albertson R; Deir R; Stewart E; Wingard K; Richardson MR; Blizard SB; Gillespie LE; Kriley CE; Rzewnicki DI; Jones DH
    Exp Cell Res; 2016 Jan; 340(1):1-11. PubMed ID: 26254261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic clonal evolution: A selection-centric perspective.
    Scott J; Marusyk A
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):139-150. PubMed ID: 28161395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of cancer driver mutations in protein kinases.
    Torkamani A; Schork NJ
    Cancer Res; 2008 Mar; 68(6):1675-82. PubMed ID: 18339846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mini-driver model of polygenic cancer evolution.
    Castro-Giner F; Ratcliffe P; Tomlinson I
    Nat Rev Cancer; 2015 Nov; 15(11):680-5. PubMed ID: 26456849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of genetic instability in heterogeneous tumors.
    Asatryan AD; Komarova NL
    J Theor Biol; 2016 May; 396():1-12. PubMed ID: 26826489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic drivers of tumourigenesis and cancer metastasis.
    Chatterjee A; Rodger EJ; Eccles MR
    Semin Cancer Biol; 2018 Aug; 51():149-159. PubMed ID: 28807546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
    Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
    Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.